This site is intended for Healthcare Professionals outside the US

MF
PV
  1. Efficacy
  2. Quality of Life Improvement

Significant, rapid, and durable improvements in QoL1

Patients treated with JAKAVI experienced durable improvement in QoL at 3-year follow-up1

COMFORT-I: Durable improvements in global health status and QoL with JAKAVI vs placebo at 3-year follow-up1

Patients treated with JAKAVI, a JAK2 Inhibitor, experienced durable improvement in Quality of Life

Adapted from: Verstovsek S et al. Abstract handout presented at: American Society of Hematology Annual Meeting, 2013.1
Based on a prespecified exploratory endpoint.
  • At 3-year follow-up, patients treated with JAKAVI experienced durable improvements in the Global Health Status/QoL and functional domains of the EORTC QLQ-C301

JAKAVI Treatment in Clinical Practice: Managing severe MF-related fatigue

Fatigue is a debilitating symptom, present in a large majority of patients with MF, and can severely impact patient quality of life. Watch the video below to learn more from Dr Ruben Mesa about managing MF-related fatigue with JAKAVI.

 

Next: Overall survival benefit with JAKAVI

EORTC QLQ C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; MF=myelofibrosis; QoL=quality of life.

Reference:

  1. Verstovsek S, Mesa RA, Gotlib J, et al; for the COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488.